3-38551391-C-T
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PS1PM1PM2PP2PP3_StrongPP5
The NM_000335.5(SCN5A):c.4978G>A(p.Gly1660Arg) variant causes a missense change. The variant allele was found at a frequency of 0.00000479 in 1,461,890 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 13/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another nucleotide change resulting in same amino acid change has been previously reported as Pathogenicin Lovd.
Frequency
Consequence
NM_000335.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCN5A | NM_001099404.2 | c.4981G>A | p.Gly1661Arg | missense_variant | 28/28 | ENST00000413689.6 | NP_001092874.1 | |
SCN5A | NM_000335.5 | c.4978G>A | p.Gly1660Arg | missense_variant | 28/28 | ENST00000423572.7 | NP_000326.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN5A | ENST00000413689.6 | c.4981G>A | p.Gly1661Arg | missense_variant | 28/28 | 5 | NM_001099404.2 | ENSP00000410257.1 | ||
SCN5A | ENST00000423572.7 | c.4978G>A | p.Gly1660Arg | missense_variant | 28/28 | 1 | NM_000335.5 | ENSP00000398266.2 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461890Hom.: 0 Cov.: 35 AF XY: 0.00000825 AC XY: 6AN XY: 727246
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:3
Uncertain significance, no assertion criteria provided | provider interpretation | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Mar 29, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 26, 2023 | Reported in association with Brugada syndrome in published literature (Kapplinger et al., 2010; Van Malderen et al., 2017; Chen et al., 2018; Wijeyeratne et al., 2020; Villarreal-Molina et al., 2021); Identified independently and in conjunction with additional variants in individuals referred for arrhythmia genetic testing at GeneDx; segregation data are limited at this time; Not observed in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24136861, 30662450, 28781330, 30203441, 30193851, 33131149, 33164571, 20129283, 32533946, 37061847, 32268277, 35305865, 35052356) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Blueprint Genetics | Jun 15, 2018 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 06, 2022 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1661 of the SCN5A protein (p.Gly1661Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with Brugada syndrome (PMID: 28781330, 30193851, 32533946). ClinVar contains an entry for this variant (Variation ID: 201523). Advanced modeling of experimental studies (such as gene expression, population dynamics, functional pathways, and cell-cycle effects in cell culture) performed at Invitae indicates that this missense variant is expected to disrupt SCN5A protein function. Experimental studies have shown that this missense change affects SCN5A function (PMID: 32533946). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
SUDDEN INFANT DEATH SYNDROME;C1832680:Dilated cardiomyopathy 1E;C1837845:Sick sinus syndrome 1;C1859062:Long QT syndrome 3;C1879286:Progressive familial heart block, type 1A;C2751898:Ventricular fibrillation, paroxysmal familial, type 1;C3151464:Atrial fibrillation, familial, 10;C4551804:Brugada syndrome 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 22, 2024 | - - |
Brugada syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Dec 22, 2016 | - - |
Cardiac arrhythmia Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Dec 07, 2022 | This missense variant replaces glycine with arginine at codon 1661 in transmembrane domain DIV of the SCN5A protein. This variant is also known as c.4978G>A (p.Gly1660Arg) based on a different transcript NM_000335. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). A functional study has shown that this variant causes a reduction in channel peak current in transfected cells (PMID: 35305865). This variant has been reported in at least 9 unrelated individuals affected with Brugada syndrome and in 3 other unrelated individuals suspected of having Brugada syndrome (PMID: 20129283, 24136861, 28781330, 32268277, 32893267, 35052356, communication with external laboratories; SCV000235504.14, SCV000748006.1). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). A different DNA change (c.4981G>C) resulting in the same amino acid change as this variant has also been reported in an individual affected with Brugada syndrome and an individual suspected of having Brugada syndrome (PMID: 20129283, 24136861). Based on the available evidence, this variant is classified as Likely Pathogenic. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 26, 2023 | The p.G1661R variant (also known as c.4981G>A), located in coding exon 27 of the SCN5A gene, results from a G to A substitution at nucleotide position 4981. The glycine at codon 1661 is replaced by arginine, an amino acid with dissimilar properties. This variant has been reported in Brugada syndrome cohorts; however, clinical details were limited in some cases (Kapplinger JD et al. Heart Rhythm, 2010 Jan;7:33-46; Van Malderen SCH et al. Circ J, 2017 Dec;82:53-61; Berthome P et al. Heart Rhythm, 2019 Feb;16:260-267; Villarreal-Molina T et al. Genes (Basel), 2021 Dec;13:[ePub ahead of print]). Based on internal structural analysis, this variant is deleterious, resulting in loss of function that significantly reduces the current density (Glazer AM et al. Am J Hum Genet, 2020 Jul;107:111-123). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at